该行料其2024至2027年的盈利年均复合增长率达24%，看好其独特的CRDMO/CTDMO模式及平台优 势，加上在中国竞争对手中拥有最多的早期项目数量，相较国内同业而言，为其中长期增长提供更强的 可见性。 智通财经APP获悉，摩根士丹利发布研报称，予药明康德(02359)"增持"评级，鉴于公司早前披露的2025 年初步业绩，因其毛利率上升，将其2026至2030年的盈利预测上调0%至3%，目标价因而由143港元升 至143.5港元。 ...

Financial Data and Key Metrics Changes - The adjusted EBITDA for Q4 2025 was $66 million, aligning with the upwardly adjusted guidance, while the full-year adjusted EBITDA reached $276 million [5][6] - The company expects 2026 adjusted EBITDA to be in the range of $280 million to $300 million, representing a 5% increase from 2025 [6][10] - Consolidated revenue decreased due to net non-same-unit activity of $26 million, but same-unit growth was 4% with pricing up just under 7% [7][10] Business Line Data and Key Metrics Changes - Patient service volumes decreased by just under 3%, with NICU days down about 2% [7][8] - Variable practice incentive compensation and salary and benefits increased on a same-unit basis, while G&A expenses rose year-over-year due to salary and travel expenses [8][9] Market Data and Key Metrics Changes - The company ended Q4 with cash of $375 million and net debt of just over $220 million, reflecting a net leverage of just under 1x [9] - The accounts receivable days sales outstanding (AR DSO) improved to 42.8 days, down almost five days year-over-year [9] Company Strategy and Development Direction - The company introduced new programs to align physicians with cash bonuses and stock price tracking elements, aiming to enhance care quality and organizational alignment [12][13] - Pediatrix is focusing on leveraging telemedicine and expanding its presence in OB hospital medicine, with plans for growth in NICUs and maternal-fetal medicine [13][15] Management's Comments on Operating Environment and Future Outlook - Management noted that the operating environment remains stable, with expectations for steady metrics in 2026, although potential impacts from ACA subsidies are acknowledged [6][10] - The company is committed to maintaining its balance sheet strength and will only consider growth opportunities that do not dilute its core pediatrics and obstetrics strengths [15][41] Other Important Information - The company plans to update on potential M&A activity in 2026, with a focus on maintaining its core strengths while exploring growth opportunities [11][41] Q&A Session Summary Question: Drivers of revenue growth for 2026 - Management indicated that revenue growth is expected to be flat in both volume and pricing for 2026 [18][19] Question: Reasons for negative patient volume year-over-year - Management attributed the decline in patient volume to tough comparisons from Q4 of the previous year [20][21] Question: Details on variable compensation expenses - Management noted that various factors influenced Q4 operations, emphasizing alignment rather than smoothing effects for future years [25][26] Question: Guidance on pricing and payer mix - Management confirmed that pricing is expected to remain steady, with no significant changes anticipated in payer mix for 2026 [30][31] Question: G&A cost reduction assumptions - Management acknowledged a small expected decline in G&A expenses year-over-year, with no specific factors identified [37][38] Question: Share repurchase plans - Management indicated a smaller amount of stock buyback is anticipated in the current guidance compared to 2025 [39][40] Question: Sustainability of pricing strength - Management highlighted strong RCM collections and favorable payer mix as key drivers of pricing strength, with expectations for stability moving into 2026 [45][46]

片忙碌 本报记者 左妍 摄 农历正月初二，上海新华医院EICU（急诊重症监护室）里灯火通明。这里没有喧嚣，只有仪器规律的 滴答声、医护人员轻而稳的脚步声，还有墙上那面普通得不能再普通的时钟。 对在这里住了两周、平生头一次在医院过年的男青年小田（化名）来说，这面钟，就是他重新认识人生 的镜子。 边治边悟健康 "我2月4日进来的。这两周不能刷手机，就只能盯着墙上的钟看。"躺在病床上的小田语气释然，"起初 它半小时半小时地走，后来变成5分钟5分钟地走，我一开始很紧张，总觉得时间过得特别慢。后来在医 生护士一遍遍的安慰和照顾下，心慢慢定下来了，踏实配合治疗。" 今年29岁的小田来自四川，经营酒吧和桌球吧，日夜颠倒、狂吃碳水是常态，体重达两百多斤。饿了就 吃，累了就睡，看似"自由放纵"的他，从没想过健康会突然亮起红灯。 当天，他突发剧烈腹痛，起初以为是吃坏肚子，嚼了两片达喜扛着。可疼痛越来越剧烈，无论怎么变换 姿势都缓解不了。朋友紧急把他送到新华医院急诊，一查竟是急性胰腺炎。 隔壁床病友一句"这病严重会要命"，再加上自己上网一搜，小田心凉了半截——急性胰腺炎发病急、进 展快，严重可致多器官衰竭。 面对危重病情，医院立刻 ...

Summary of Leidos Conference Call Company Overview - **Company Name**: Leidos - **Market Position**: A $17.5-$18 billion company with 48,000 employees, primarily serving the U.S. government in federal IT, national security, intelligence, health, and veterans health sectors. Significant presence in Australia and the U.K. [4][5] Core Business Lines - **Business Sectors**: 1. **Digital Modernization**: Core focus on IT services. 2. **Defense**: Consolidated defense products into one sector, focusing on maritime and space growth pillars. 3. **Homeland**: Encompasses work related to Australia, the U.K., energy, and Department of Homeland Security (DHS). 4. **Health**: Services for veterans and active service members. 5. **Intelligence**: Focused on serving the intelligence community effectively. [7][8][9] Market Trends and Opportunities - **Defense Budget Growth**: Anticipation of the Department of Defense budget exceeding $1 trillion by 2027, potentially reaching $1.5 trillion, which is expected to benefit Leidos' defense business. [10][11] - **Agency Spending**: Expectation of increased spending from agencies due to the reconciliation package, particularly in TSA and FAA modernization. [11][12] - **Intelligence Community Growth**: Increased budget allocation for the intelligence community, with Leidos positioned to play a significant role. [14] - **Digital Modernization**: Emphasis on AI as a growth pillar, with plans to leverage AI for business growth. [14][15] Strategic Initiatives - **R&D Investments**: Increased internal R&D spending from 17% to 24% to enhance technological capabilities and service offerings. [29][32] - **Acquisitions**: Recent acquisition of EnTrust to enhance capabilities in the energy sector, with plans for integration and efficiency improvements. [35][39] - **AI Strategy**: Leidos has been proactive in adopting AI, deploying OpenAI across desktops for employees to enhance business processes. [55][56] Financial Performance - **Record Earnings**: Despite headwinds, Leidos reported record earnings, cash flow, and profitability, with a profit margin of 14.1% last year. [5][15] - **Growth Expectations**: Anticipation of continued growth in 2026, driven by established growth pillars and new opportunities in modernization projects. [75] Challenges and Responses - **DOGE Administration**: Viewed as an opportunity rather than a threat, with proactive engagement to improve government efficiency. [17][18] - **Market Differentiation**: Leidos is recognized as a multifaceted service provider, distinguishing itself from peers in the federal services and IT sector. [24][25] Conclusion - **Outlook**: The company is optimistic about its trajectory, with a strong execution engine and clear growth pillars, expecting 2026 to be another exceptional year. [75]

（来源：千龙网） 近日，以"汇聚专业人才，深化CHIVA技术协作，共筑高原专病诊疗新高地"为主题的CHIVA专病中心座 谈会暨协作签约仪式在山南市乃东区中心医院举行。此次协作创新采用"院校合作+院院合作"双模式， 重点推进先进诊疗技术高原转化、本土医疗骨干培养及高原医学研究三大任务。 据悉，CHIVA技术作为微创血流矫正技术，针对下肢静脉曲张具有创伤小、恢复快、保留隐静脉功能 等优势，通过超声精准定位返流点并矫正异常血流，可实现"首日检查、次日手术、三四日出院"的高效 诊疗模式。 在座谈会上，长江大学附属荆州市第一人民医院与乃东区中心医院正式签署《医疗协作共建协议》。根 据协议，双方将聚焦CHIVA技术的高原转化应用，通过专家驻点坐诊、订单式进修培训、远程病例讨 论等方式，培育本土医疗骨干，并联动科研平台，围绕高原血管疾病开展临床研究，力争形成具有地域 特色的"乃东数据"与诊疗标准。 ...

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.43%. A quarter ago, it was expected that this company would post earnings of $0.16 per share when it actually produced earnings of $0.18, delivering a surprise of +12.5%.Over the last four quarters, the company ha ...

"医生，这两天我膝盖一直疼，假期你们社区的大夫还上班吗？" "赵奶奶，我们假期上班，现在就去你家看看。" 2月15日，农历腊月二十八，家家户户都在忙着备年货、扫尘垢。抱着试一试的心态，83岁的郑州市民 赵桂芝老人在微信群里的一句询问，很快就得到了郑州市第九人民医院领办的京广路冯春社区卫生服务 中心护士长王晓慧的贴心回复。 "马上过年了，没想到你们还能来家服务，真是太感谢了。"位于长江东路的春天花园小区，赵奶奶的家 人早早把门打开，热情地将王晓慧一行人迎进门。寒暄过后，随行的医生王丽萍便拿出血压仪，仔细帮 老人测量了血压、脉搏，并进行了肺部听诊。在确认指标稳定后，开始为老人双膝进行按摩，询问疼痛 频率，同时搭配腿部的关节活动度训练测试膝盖的疼痛程度。 一番娴熟的操作过后，王丽萍判断"事儿不大，要注意休息"，随后对老人这段时间的生活起居情况进行 了询问。了解到老人近期经常独自外出买菜，就叮嘱她及家人："最近天气暖和了不少，但早晚温差很 大，商场和超市里人多，奶奶还是要尽量减少外出，饮食要坚持清淡为主。"每一处细节、每一句提 醒，逐渐缓解了家人们的担忧。 赵桂芝老人是该中心第一批建立家庭病床的患者，患有高血压、糖尿 ...

Financial Data and Key Metrics Changes - In 2025, the company recorded revenues of $17.2 billion, an increase of 3.1% year-over-year, while Q4 revenues were $4.2 billion, a decrease of 3.6% year-over-year [33][5] - Adjusted EBITDA margin for 2025 was 14.1%, a year-over-year increase of 120 basis points, while Q4 adjusted EBITDA margin was 13.2%, up 160 basis points year-over-year [5][35] - Non-GAAP diluted earnings per share (EPS) for 2025 was $11.99, a 17% increase from the previous year, with Q4 EPS at $2.76 [37][5] - Free cash flow for 2025 was $1.63 billion, representing a 104% conversion rate [46] Business Line Data and Key Metrics Changes - All four segments contributed to revenue growth in 2025, with Defense Systems showing robust revenue growth due to increased production of munitions [44][38] - The Health and Civil segment saw a slight decline in Q4 revenues but an overall increase for the year, with managed health services being a moderate headwind in Q4 [40][41] - The Commercial and International segment experienced growth driven by improved performance in the UK and increased engineering support for commercial utilities [43] Market Data and Key Metrics Changes - The company reported a book-to-bill ratio of 1.3 times for both Q3 and Q4 of 2025, with net bookings of $5.6 billion in Q4 [6][7] - Funded backlog increased by 15% year-over-year, indicating strong demand and alignment with administration priorities [7] Company Strategy and Development Direction - The company is executing its NorthStar 2030 strategy, focusing on growth pillars such as defense, health, and energy infrastructure [12][21] - Recent acquisitions, including Kudu Dynamics and the planned acquisition of ENTRUST Solutions Group, are aimed at enhancing capabilities and market position [15][16] - The company is increasing capital expenditures to $350 million to support growth initiatives and production capacity [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate challenges, including a government shutdown, and highlighted a strong pipeline of opportunities [4][70] - The outlook for 2026 includes expected revenue growth between $17.5 billion and $17.9 billion, with a mid-13% adjusted EBITDA margin [49][50] - Management anticipates that the impact of strategic investments will become more evident in 2026, with a focus on sustaining growth and profitability [31][32] Other Important Information - The company plans to triple its capital expenditure investments to support key national priority projects [20] - The organizational structure has been realigned to better execute the NorthStar strategy, with a focus on five sectors [22][26] Q&A Session Summary Question: Investment areas for additional CapEx - Management confirmed investments in co-development opportunities with the Department of War and other sectors, including health and transportation [62][63] Question: Early year growth expectations - Management indicated lower growth in the first half of 2026, with expectations for acceleration in the second half due to new program wins and a robust business development pipeline [66][68] Question: Book-to-bill expectations - Management expressed confidence in continued robust order activity and a strong pipeline, with a focus on new business and recompete opportunities [75][76] Question: VA medical exam recompete - Management highlighted their commitment to maintaining market share in the health sector and discussed ongoing investments to improve service efficiency [86][89] Question: FY 2026 growth guidance - Management noted potential for growth acceleration in defense and FAA projects, with no one-time items included in the guidance [95][97] Question: Product and defense tech updates - Management provided updates on key programs like IFPC and hypersonics, expressing optimism about their growth potential [102][104]

Core Viewpoint - Labcorp Holdings (LH) reported quarterly earnings of $4.07 per share, exceeding the Zacks Consensus Estimate of $3.95 per share, and showing an increase from $3.45 per share a year ago, indicating a positive earnings surprise of +2.98% [1] Financial Performance - The company posted revenues of $3.52 billion for the quarter ended December 2025, which was below the Zacks Consensus Estimate by 0.97%, but an increase from $3.33 billion year-over-year [2] - Over the last four quarters, Labcorp has surpassed consensus EPS estimates four times, but has only topped consensus revenue estimates once [2] Stock Performance - Labcorp shares have increased approximately 12.7% since the beginning of the year, contrasting with a 0.1% decline in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $4.12 on revenues of $3.52 billion, and for the current fiscal year, it is $17.62 on revenues of $14.69 billion [7] - The trend of earnings estimate revisions for Labcorp was mixed ahead of the earnings release, which may change following the recent report [6] Industry Context - The Medical Services industry, to which Labcorp belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Financial Data and Key Metrics Changes - In 2025, the company recorded revenues of $17.2 billion, an increase of 3.1% year-over-year, while Q4 revenue was $4.2 billion, a decrease of 3.6% year-over-year [18][19] - Adjusted EBITDA margin for 2025 was 14.1%, up 120 basis points year-over-year, and for Q4, it was 13.2%, an increase of 160 basis points year-over-year [4][20] - Non-GAAP diluted earnings per share (EPS) for 2025 was $11.99, a 17% increase from the previous year, with Q4 EPS at $2.76 [20][21] - Free cash flow for 2025 was $1.63 billion, representing a 104% conversion rate [25] Business Line Data and Key Metrics Changes - All four segments contributed to revenue growth in 2025, with Defense Systems showing robust revenue growth due to increased production of munitions [21][24] - The Health and Civil segment saw a slight revenue increase for the year but a decrease in Q4, impacted by the transition of electronic health records [23] - The Commercial and International segment experienced growth driven by improved performance in the UK and increased engineering support for commercial utilities [24] Market Data and Key Metrics Changes - The company reported a book-to-bill ratio of 1.3 times for both Q4 and the third quarter of 2025, with a year-over-year funded backlog increase of 15% [5][19] - The underlying business showed strong growth across the portfolio, particularly in integrated air defense, intelligence community mission support, energy infrastructure, and full-spectrum cyber [19] Company Strategy and Development Direction - The company is executing its North Star 2030 strategy, focusing on innovation and aligning with administration priorities [8][12] - Significant investments are being made in growth pillars, including a planned tripling of capital expenditures to $350 million in 2026 [11][30] - The company is pursuing co-investment opportunities with the Department of Defense and other agencies to enhance its growth strategy [11][37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate challenges, including a government shutdown, and highlighted strong demand for its services [4][19] - The outlook for 2026 includes expected revenue growth between $17.5 billion and $17.9 billion, with a mid-13s Adjusted EBITDA margin [28] - Management anticipates that the impact of corporate investments will become evident in 2026, with a focus on sustaining growth and profitability [27][30] Other Important Information - The company plans to acquire Entrust Solutions Group for $2.4 billion, which is expected to enhance its capabilities in the energy sector [26][30] - The organizational structure has been realigned to better execute the growth strategy, with a focus on five sectors [12][13] Q&A Session Summary Question: Investment areas for additional CapEx - Management confirmed investments in co-development opportunities with the Department of Defense and other sectors, including health and transportation [37][39] Question: Early part of the year growth expectations - Management indicated lower growth in the first half of 2026, with expectations for acceleration in the second half due to new program wins and a robust business development pipeline [40][42] Question: Book-to-bill performance and future expectations - Management highlighted a strong pipeline and backlog, with expectations for continued order growth and a robust business development function [46][48] Question: VA medical exam recompete expectations - Management expressed confidence in maintaining competitiveness in the VA medical exam space, with plans for a recompete bid expected mid-year [56][59] Question: Capital allocation and M&A opportunities - Management stated that while there are significant capital commitments for the Entrust acquisition, they remain open to other shareholder-friendly capital deployments [84] Question: AI impact on software development costs - Management views AI as a force multiplier that enhances efficiency and effectiveness rather than a threat to pricing [91][93] Question: Maritime program updates - Management discussed ongoing dialogues with the Department of the Navy regarding medium unmanned surface vehicles and the importance of payload capabilities [101][102]